文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

关于 CpG DNA 及其作为疫苗佐剂的最新进展。

Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

机构信息

Department of Clinical Oncology, Tohoku University, Japan.

出版信息

Expert Rev Vaccines. 2014 Feb;13(2):299-312. doi: 10.1586/14760584.2014.863715. Epub 2013 Nov 26.

DOI:10.1586/14760584.2014.863715
PMID:24308579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6335645/
Abstract

CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Here, we review recent progress in understanding the mechanism of action of CpG ODN and provide an overview of human clinical trial results using CpG ODN to improve the vaccines for cancer, allergy and infectious disease.

摘要

CpG 寡核苷酸（ODN）是一种免疫调节合成寡核苷酸，旨在特异性激动 Toll 样受体 9。在这里，我们回顾了理解 CpG ODN 作用机制的最新进展，并概述了使用 CpG ODN 改善癌症、过敏和传染病疫苗的人体临床试验结果。

相似文献

[1]
Recent progress concerning CpG DNA and its use as a vaccine adjuvant.

Expert Rev Vaccines. 2013-11-26

[2]
CpG Oligonucleotides as Vaccine Adjuvants.

Methods Mol Biol. 2021

[3]
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.

Vaccine. 2014-11-12

[4]
CpG 7909: PF 3512676, PF-3512676.

Drugs R D. 2006

[5]
Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism.

Eur J Immunol. 2006-1

[6]
Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.

J Control Release. 2018-4-25

[7]
Toll-like Receptor 9 Agonists as Adjuvants for Nanoparticle-Based Nicotine Vaccine.

Mol Pharm. 2021-3-1

[8]
CpG DNA as a vaccine adjuvant.

Expert Rev Vaccines. 2011-4

[9]
Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.

Int Immunol. 2009-7

[10]
Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

Eur J Immunol. 2006-1

引用本文的文献

[1]
Development of an Effective Single-Dose PCV2/CSFV Bivalent Subunit Vaccine Against Classical Swine Fever Virus and Porcine Circovirus Type 2.

Vaccines (Basel). 2025-7-8

[2]
Gut microbiota shapes cancer immunotherapy responses.

NPJ Biofilms Microbiomes. 2025-7-25

[3]
Exploiting FcRn engagement of an albumin-CpG oligonucleotide covalent conjugate for potent TLR9 immune induction.

J Biol Chem. 2025-4-11

[4]
The recombinant truncated envelope protein of West Nile virus adjuvanted with Alum/CpG induces potent humoral and T cell immunity in mice.

Biosaf Health. 2023-6-27

[5]
Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant.

Virol J. 2025-1-8

[6]
Enhancing antibody levels and T cell activity of quadrivalent influenza vaccine by combining it with CpG HP021.

Sci Rep. 2024-12-28

[7]
Developing a potent vaccine against : critical considerations and challenges.

Expert Rev Mol Med. 2024-11-25

[8]
A novel immunomodulating peptide with potential to complement oligodeoxynucleotide-mediated adjuvanticity in vaccination strategies.

Sci Rep. 2024-11-5

[9]
CpG oligodeoxynucleotide-coated chitosan nanoparticles enhance macrophage proinflammatory phenotype in vitro.

Clin Exp Immunol. 2025-1-21

[10]
Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective.

Vaccines (Basel). 2024-8-22

本文引用的文献

[1]
Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection.

Hepatology. 2013-12-20

[2]
β-Defensin 2 and 3 promote the uptake of self or CpG DNA, enhance IFN-α production by human plasmacytoid dendritic cells, and promote inflammation.

J Immunol. 2013-6-17

[3]
PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-γ response and enhances survival.

J Cancer Ther. 2013-1-1

[4]
The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV™ review.

Hum Vaccin Immunother. 2013-5-31

[5]
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.

J Clin Oncol. 2013-5-28

[6]
Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.

Vaccine. 2013-5-22

[7]
Randomized, double-blind, placebo-controlled, safety and immunogenicity study of 4 formulations of Anthrax Vaccine Adsorbed plus CPG 7909 (AV7909) in healthy adult volunteers.

Vaccine. 2013-5-10

[8]
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.

J Allergy Clin Immunol. 2013-2-4

[9]
Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells.

Nanomedicine. 2013-1-22

[10]
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.

Eur J Immunol. 2012-8-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索